Lipocine Inc. (LPCN)

NCM – Real Time Price. Currency in USD

2.33

+0.01 (0.43%)

At close: May 12, 2026, 4:00 PM EDT

2.32

-0.01 (-0.43%)

Pre-market: May 13, 2026, 4:00 AM EDT

07.05.2026

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.

07.05.2026

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2026 and provided a corporate update. Neuroactive Steroids (NAS) LPCN 1154 for Postpartum Depression ("PPD") In April 2026, Lipocine announced topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression.

06.04.2026

What's Going On With Lipocine Stock On Monday?

On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).

06.04.2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's executive officers and whether investor losses may be recovered under federal securities laws.

02.04.2026

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 in the overall study population, and the primary endpoint was not met.

02.04.2026

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54) who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained through day 30 In the overall population, LPCN 1154 was well tolerated and demonstrated a differentiated safety profile with no reported adverse event, including somnolence or dizziness, occurring in more than 5% of the LPCN 1154-treated participants The Company plans to evaluate all available options going forward SALT LAKE CITY, April 2, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). For more information on the trial design, refer to clinicaltrials.gov: NCT06979544.

10.03.2026

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the full year ended December 31, 2025 and provided a corporate update. "We believe 2025 was a pivotal year for Lipocine as we continue to advance our pipeline and expand our market presence.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

06.04.2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

02.04.2026

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

10.03.2026

Lipocine Inc. (LPCN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lipocine Inc. (LPCN)

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

What's Going On With Lipocine Stock On Monday?

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Videos

No Data

Press releases

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

What's Going On With Lipocine Stock On Monday?

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Videos

No Data

Press releases

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Search stocks

Lipocine Inc. (LPCN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lipocine Inc. (LPCN)

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

What's Going On With Lipocine Stock On Monday?

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Videos

No Data

Press releases

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

What's Going On With Lipocine Stock On Monday?

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Videos

No Data

Press releases

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025